type-B receptor 4)-a member of the Eph RTK family-is the embryonic venous determinant. We previously showed that Eph-B4 mediates vein graft adaptation and AVF maturation with distinct patterns of altered vessel identity. [26] [27] [28] Successful AVF maturation also requires venous adaptation to a fistula environment that is similar to the arterial environment but is characterized by distinct biology and hemodynamics compared with vein graft adaptation. 29 Although Cav-1 is a determinant of Eph-B4-mediated vein graft adaptation, 27 the role of Cav-1 during AVF maturation has not been investigated. Because Eph-B4 expression increases during AVF maturation, 28 but not vein graft adaptation, 26 we hypothesized that Cav-1 mediates AVF maturation and that endothelial Cav-1 is a critical regulator of Eph-B4-mediated AVF maturation through inhibition of eNOS activity.
Methods

Human Specimens
The principles outlined in the Declaration of Helsinki were followed, and approval of the Veterans Affairs institutional Human Investigation Committee was obtained; informed consent to use the samples was obtained. Deidentified specimens of AVF and control veins were obtained during revision operations of functional AVF. 28 Because most fistulae are currently revised by endovascular methods, open revisions are no longer performed regularly, and thus, only n=3 human specimens were available for analysis.
Mice
All animal experiments were performed in strict compliance with federal guidelines and with approval from the Yale University IACUC (Institutional Animal Care and Use Committee). Appropriate anesthesia and analgesia were given as described previously. 30, 31 Mice used for this study included WT C57BL6/J (WT), Cav-1 KO (knockout), Cav-1 RC (Cav-1 endothelial reconstituted), or Eph-B4 heterozygous (Eph-B4 het) mice. C57BL/6 WT, Cav-1 KO, and EphB4 +/− mice were purchased (The Jackson Laboratory). Cav-1 RC mice were generated on the Cav-1 KO genetic background and maintained as described previously. 18, 32 All mice were male and 9 to 11 weeks of age; only male mice were studied because female sex is the only predictor of nonmaturation of human AVF in some studies. 33 
EphB4
+/− mice were B6.129S7 background and bred to C57BL/6 mice for at least 10 additional generations so that littermate mice were used for reference groups. 27 Estimated sample sizes were calculated using a power analysis (Graphpad Statmate 2.00 software); 6 animals per sample would be needed for morphometry to allow detection of a difference in neointimal hyperplasia between groups assuming α=0.05, 80% power, SD=1.0 micron, and difference between groups of 2 microns. Fewer animals are needed for qPCR (quantitative polymerase chain reaction) and Western blotting because these studies are more accurate, with smaller SD, than morphometry of histology. However, when we found a significant difference with a smaller sample number, additional animal experiments were not performed to prevent unnecessary waste of precious resources and animals.
Infrarenal Aortocaval Fistula Model
Infrarenal aortocaval fistulae were created as described previously. 31 Briefly, an aortocaval fistula was created by needle puncture from the aorta into the inferior vena cava (IVC). Sham procedures consisted of midline laparotomy without the AVF creation. The presence of the AVF was confirmed by direct visualization of pulsatile arterial blood flow in the IVC at creation and harvest, as well as by serial Doppler ultrasound (Vevo770 High-Resolution Imaging System; VisualSonics, Inc, Toronto, Ontario, Canada). In the latter, increased diastolic flow through the aorta and a high-velocity pulsatile flow within the IVC were used to confirm the presence of an AVF during postoperative examinations.
In Vivo Measurement of Fistula Patency and Dilation
Doppler ultrasound was also used to measure the diameter of the IVC and aorta during the study period as described previously. 30 Measurements were performed the day before operation (preoperative values) and serially postoperatively.
Recombinant Peptide Experiments
Peptides, corresponding to the scaffolding domain of Cav-1 (amino acids 82-101; DGIWKASFTTFTVTKYWFYR), were synthesized as a fusion peptide to the C terminus of the AP (antennapedia) internalization sequence (RQIKIWFQNRRMKWKK) by standard Fmoc chemistry (United BioSystems, Herndon, VA). 34 Mice were given control (truncated) AP or AP-Cav peptides, or cavtratin, via intraperitoneal injection (3.0 mg/kg) once daily beginning on day 0 and continuing throughout the experiments.
Eph-B4 Stimulation In Vivo
Eph-B4 was stimulated with Ephrin-B2/Fc (R&D, Minneapolis, MN). Twenty-four hours before AVF creation, mice underwent ultrasound for measurement of preoperative vessel diameter as described above. While still under isoflurane anesthesia, Ephrin-B2/Fc (20 µg) diluted in 200 µL PBS was delivered by intraperitoneal injection; control mice received an equal volume injection of vehicle (PBS). The next day, an infrarenal aortocaval AVF was created as described above. Additional intraperitoneal injections of Ephrin-B2/Fc or control vehicle were delivered every 48 hours beginning on postoperative day 1 and continued throughout the study period.
Histology
The venous limb of the AVF or control IVC from sham-operated mice was extracted en bloc after circulatory flushing with normal saline followed by 10% formalin. The tissue block was then embedded in paraffin and cut in 5-μm cross sections. For wall thickness measurements, cross sections were obtained at 0.2 to 5.0 mm cranial to the AVF and stained with elastin van Gieson stain to highlight the elastic lamina. Digital images for the sections were captured with a microscopic system (BX40; Q Color 5; Olympus America, Center Valley, PA) and were analyzed using ImageJ 1.48v software (National Institutes of Health, Bethesda, MD). Wall thickness, or intima+media thickness, was measured at 8 points (45°) around the vessel circumference and then averaged for each sample. 28 Additional unstained cross sections in this same region (0.2-5.0 mm cranial to the AVF) were used for immunohistochemistry (IHC) or for immunofluorescence. Technologies) . Digital fluorescence images were captured, and intensity of immunoreactive signal was measured using Image J software (National Institutes of Health, Bethesda, MD). Intensity of merge signal was determined by applying a color threshold selective for yellow signal. For each antibody, standard quality control procedures were undertaken to optimize antigen retrieval, primary antibody dilution, secondary antibody detection, and other factors for both signal and noise.
Nonstandard Abbreviations and Acronyms
Western Blotting
The venous limb of the AVF was harvested and treated with RIPA lysis buffer containing protease and phosphatase inhibitors (Roche). 
RNA Extraction and Quantitative Reverse Transcriptase Polymerase Chain Reaction
The venous limb of the fistula or the IVC (sham) was harvested after isolation from surrounding arterial and connective tissues, and total RNA was isolated using RNeasy Mini Kit with digested DNase I (Qiagen, Valencia, CA). RNA quality was confirmed using the 260/280 nm ratio (Nanodrop; Thermo Scientific, Wilmington, DE). Reverse transcription was performed using SuperScript III First-Strand Synthesis Supermix (Invitrogen; Life Technologies, Carlsbad, CA). Real-time PCR was performed using iQ SYBR Green Supermix (Bio-Rad, Hercules, CA). Samples were amplified for 35 cycles using the iQ5 Real-Time PCR Detection System (Bio-Rad). Correct target amplification and exclusion of nonspecific amplification was confirmed by 1.5% agarose gel electrophoresis; primer efficiencies were determined by melt curve analysis. Primers used are as listed in the Table. All samples were normalized by GAPDH RNA amplification.
Transmission Electron Microscopy
IVC tissue samples were fixed with 2.5% glutaraldehyde in 0.1 mol/L cacodylate buffer, postfixed with OsO4 (osmium tetroxide), and stained with uranyl acetate and lead citrate. Microtome sections were examined under a FEI Tecnai Biotwin TEM. Caveolae were identified by their characteristic flask shape, size (50-100 nm), and location at the plasma membrane.
35
Cell Culture
Mouse lung ECs isolated from male mice were prepared as described previously 36 and were cultured in EBM-2 (endothelial basal media-2) supplemented with 20% fetal bovine serum, L-glutamine, penicillin/streptomycin, and the EGM-2 Bulletkit (Lonza).
NO Release Analysis
NO production by mouse lung EC was analyzed as described previously. 37 In brief, conditioned medium was examined 24 hours after cavtratin treatment. The media was processed for the measurement of nitrite (NO 2 − ) by an NO-specific chemiluminescence analyzer (Sievers).
In Vitro Whole Cell Lysate Isolation
Cells were treated with RIPA (radioimmunoprecipitation assay) lysis buffer containing protease and phosphatase inhibitor cocktail. Cells were then scraped, sonicated, and centrifuged.
Statistical Analysis
All data were analyzed using Prism 7 software (GraphPad Software, Inc, La Jolla, CA). Error bars depict the SEM. The Shapiro-Wilk test was performed to analyze normality; F tests were performed to evaluate homogeneity of variances. For 2-group comparisons with normally distributed data, the unpaired Student t test was used for data with equal variances among groups, and the unpaired Student t test (with Welch correction) was used for data with unequal variances. For multiple group comparisons with normally distributed data, the 1-way ANOVA followed by the Tukey post hoc test was used. For data that were not normally distributed, the nonparametric MannWhitney U test was used for 2-group comparisons, and the KruskalWallis was performed for multiple groups. Patency outcomes were analyzed with the use of a Cox proportional-hazards model. KaplanMeier curves were constructed to display the distribution of occlusion events detected over time. P <0.05 was considered significant.
Results
Increased Cav-1 Expression and Caveolae Formation During AVF Maturation
To determine whether Cav-1 regulates AVF maturation, we evaluated Cav-1 expression in human and mouse AVF. In functional, mature human AVF, expression of immunoreactive Cav-1 protein was increased compared with control vein 
Gene
Forward Reverse Figure 1A) . Similarly, in a mouse AVF model, there was increased expression of Cav-1 protein in the AVF compared with sham-operated veins ( Figure 1B) ; transcripts of Cav-1 were increased in the AVF from day 3 to day 21 compared with control veins ( Figure 1C ). The increased Cav-1 in AVF colocalized predominantly with VWF-positive cells, with 3.8× more immunoreactivity colocalized with VWF-positive cells compared with α-SMA (α-smooth muscle actin)-positive cells ( Figure 1D ). Venous endothelium of control veins or AVF was examined with transmission electron microscopy; the number of caveolae per length of plasma membrane was increased 1.9-fold in the endothelium of AVF compared with control veins ( Figure 1E ). These results show that in AVF, there is increased Cav-1 expression and caveolae formation in the venous endothelium.
Absence of Cav-1 Facilitates AVF Remodeling
Venous remodeling that occurs during AVF maturation in this model is characterized by ≈2.4-fold increased wall thickening and 1.5-fold increased dilation compared with mice with sham operations. 31 Because our data show increased Cav-1 expression during AVF maturation (Figure 1) , we hypothesized that Cav-1 regulates flow-mediated venous remodeling such as occurs during AVF maturation. To determine whether reduced Cav-1 function plays a functional role to regulate AVF maturation, we examined AVF maturation in Cav-1 KO mice. Cav-1 KO mice have similar body weight and similar baseline wall thickness and diameter of their vena cavae and aortae compared with control mice ( Figure IA through IF in the onlineonly Data Supplement). As expected, the veins of Cav-1 KO mice did not have any detectable Cav-1 expression but had increased eNOS phosphorylation ( Figure IG in the onlineonly Data Supplement). 32, 34, 38, 39 Similarly, Cav-1 expression was only minimally detectable in EC derived from Cav-1 KO mice compared with that detectable in control mice, and there was increased eNOS phosphorylation ( Figure 2A ) and nitrite released from EC derived from Cav-1 KO mice ( Figure 2B ).
AVF were created in control and Cav-1 KO mice. Postoperative survival was reduced in Cav-1 KO mice (46.7%, 7/15) compared with control mice (91.7%, 11/12; P=0.0187, log-rank); however, the patency rate of AVF (day 21) was similar between Cav-1 KO mice (100%, 15/15) and WT mice (91.7%, 11/12; P=0.4346, log-rank; Figure IH and II in the online-only Data Supplement). Despite lack of any Figure 2C) ; both total wall thickness (30.9±2.6 versus 15.6±2.0 μm; n=7; P=0.0005) and neointimal thickness (19.0±3.1 versus 7.0±1.1 μm; n=7; P=0.002) were increased in AVF of Cav-1 KO mice (day 21). Serial Doppler ultrasound showed that AVF in Cav-1 KO mice had larger diameter, relative to baseline, compared with AVF in control mice ( Figure 2D ), despite lower blood pressure in Cav-1 KO mice 32 and similar blood flow velocity and shear stress in the AVF of control and Cav-1 KO mice ( Figure IIB in the online-only Data Supplement). Interestingly, there was no difference in relative diameter of the artery leading into the AVF ( Figure 2D ).
In AVF created in Cav-1 KO mice (day 21), there was no detectable Cav-1 expression but increased phosphorylated and total eNOS immunoreactivity compared with AVF created in control mice ( Figure 2E ), despite similar total eNOS expression in the IVC at baseline ( Figure IG in the online-only Data Supplement); increased total eNOS expression is consistent with increased endothelium and neointima in the fistula. Immunofluorescence showed increased intensity of both p-eNOS (2.4-fold) and eNOS (1.8-fold) in the endothelium of Cav-1 KO AVF compared with control AVF, with similar VWF intensity in the 2 groups ( Figure 2F ). Increased wall thickening in the AVF of Cav-1 KO mice was characterized by increased numbers of proliferating cells with no decrease in apoptotic cells ( Figure 2G and 2H) ; as expected, the increased numbers of α-SMA-positive cells in AVF of Cav-1 KO mice did not have any Cav-1 immunoreactivity ( Figure 2I ).
These data suggest that Cav-1 regulates eNOS activity in vivo during AVF remodeling; accordingly, we assessed eNOS function in WT mice. In WT mice, the ratio of phospho-eNOS to total eNOS increased in the AVF compared with sham-operated veins ( Figure IIIA in the online-only Data Supplement). eNOS KO mice had AVF with thinner walls compared with control mice ( Figure 2J ) and with larger diameter consistent with elevated blood pressure ( Figure IIIB in the onlineonly Data Supplement); treatment with L-NAME-a global NOS (NO synthase) inhibitor-similarly resulted in thinner AVF walls with larger diameter compared with control mice ( Figure 2K ; Figure IIIC in the online-only Data Supplement). These data suggest that eNOS is functional during AVF remodeling, and thus Cav-1 regulation of eNOS may be a mechanism of venous remodeling during AVF maturation.
In toto, these data suggest that global deletion of Cav-1 regulates venous remodeling in the fistula environment, characterized by increased venous wall thickness and diameter, as well as increased proliferation of smooth muscle cells, and is consistent with the inhibitory effect of Cav-1 on downstream function, including eNOS.
34,40
Endothelial Cav-1 Regulates Eph-B4-Mediated AVF Remodeling
We have previously shown that the venous determinant Eph-B4 regulates AVF remodeling, 28 similar to the function of Cav-1 ( Figure 2 ). Eph receptors translocate to or reside within caveolae, 20, 21, 23, 41 and stimulated Eph-B4 associates with Cav-1 in vitro and in vivo, 27 suggesting involvement of Cav-1 in Eph-B4 signaling. To directly test whether endothelial Cav-1 acts as a mediator of Eph-B4 during venous remodeling such as occurs during AVF maturation, Eph-B4 function was stimulated with its ligand Ephrin-B2/Fc in control mice, Cav-1 KO mice, and Cav-1 KO mice with specific EC Cav-1 RC mice. 18, 32 As expected, control mice treated with Ephrin-B2/Fc showed less AVF wall thickness at day 21; however, AVF in Cav-1 KO mice had increased wall thickness that was not responsive to Ephrin-B2/Fc; AVF wall thickness in Cav-1 RC mice showed a trend toward response to Ephrin-B2/Fc (26% reduction; P=0.07; Figure 3A) . After Ephrin-B2/Fc treatment, there were reduced numbers of proliferating cells in AVF of control mice but not in AVF of Cav-1 KO mice; there were reduced numbers of proliferating cells in AVF of Cav-1 RC mice ( Figure 3B ). Ephrin-B2/Fc treatment did not change the numbers of apoptotic cells in the AVF of any of these groups ( Figure 3C) .
Similarly, there was less outward remodeling during AVF maturation in control mice treated with Ephrin-B2/Fc; Cav-1 KO mice treated with Ephrin-B2/Fc showed no difference in outward remodeling, whereas Cav-1 RC mice showed less dilation in response to Ephrin-B2/Fc, similar to the responsiveness of control mice ( Figure 3D ). Ephrin-B2/Fc treatment also decreased the intensity of p-eNOS immunoreactivity in the AVF endothelium of control mice but not in Cav-1 KO mice; this reduction was partially restored in Cav-1 RC mice (P=0.0325; Figure 3E ). eNOS KO mice treated with Ephrin-B2/Fc did not show reduced wall thickness, but this was not surprising because eNOS KO mice did not show any wall thickening at baseline ( Figure IIID in the online-only Data Supplement; Figure 2J ). These results suggest that Eph-B4-mediated AVF remodeling is abolished in Cav-1 KO mice and partially restored in endothelial Cav-1 RC mice; endothelial Cav-1 regulation of Eph-B4-mediated AVF remodeling is associated with diminished eNOS phosphorylation and cell proliferation.
Augmentation of Cav-1 Signaling Regulates Flow-Mediated Venous Remodeling and Improves AVF Patency
Because endothelial Cav-1 inhibits wall thickening and diameter expansion during AVF maturation (Figure 2) , and reduced wall thickness is associated with improved AVF patency, 28 we hypothesized that simulation of Cav-1 function would enhance AVF patency. Therefore, we used cavtratin-a chimeric peptide with a cellular internalization sequence fused to the Cav-1 scaffolding domain that enhances Cav-1 function and inhibits eNOS activity 34 -to alter flow-mediated venous remodeling during AVF maturation. As expected, cavtratin inhibited nitrite release from EC in vitro ( Figure 4A ). WT mice treated systemically with cavtratin showed less thickened AVF walls (day 21) compared with control mice ( Figure 4B ). In addition, cavtratin treatment was associated with less diameter expansion of the AVF but not the artery compared with control mice ( Figure 4C ). AVF in mice treated with cavtratin showed reduced numbers of proliferating cells with no increase in apoptotic cells in the AVF (Figure 4D and 4E) . In the mouse aortocaval AVF model, there is increased neointimal hyperplasia with wall thickening and reduced patency between days 21 and 42, similar to the aggressive juxta-anastomotic neointimal hyperplasia that is associated with high rates of early failure of human AVF. 31 In WT mice treated with cavtratin, AVF had significantly increased patency by day 42 (P=0.0275, log-rank); at day 42, AVF were occluded in 0 of 12 mice (0%) receiving cavtratin but were occluded in 4 of 13 mice (30.8%) receiving control peptide ( Figure 4F ). Consistent with this data, cavtratin-treated mice showed less thickened AVF walls (P=0.0261) and less outward venous remodeling (P=0.0474) at day 42 ( Figure 4G and 4H). At day 42, the AVF of mice treated with cavtratin showed less p-eNOS immunoreactivity in the AVF (Western blot of whole vessel lysate), without any change in p-Akt1 (phosphoAkt1) immunoreactivity, compared with AVF of control mice ( Figure 4I) ; immunofluorescence showed reduced p-eNOS immunoreactivity in the endothelium of cavtratin-treated mice ( Figure 4J ). These data suggest that stimulation of Cav-1 signaling with cavtratin improves AVF patency and is associated with less wall thickness, less outward remodeling, and less eNOS phosphorylation during AVF maturation.
Because Cav-1 activity is associated with reduced wall thickness ( Figures 2C, 2I, 4B , and 4G), and Cav-1 mediates Eph-B4-mediated AVF remodeling (Figure 3 ), we next determined whether stimulation of Cav-1 activity could rescue diminished Eph-B4 function during AVF remodeling, that is Cav-1 is downstream of Eph-B4. Eph-B4 heterozygous mice have similar body weight, baseline IVC and aorta diameter, and similar postoperative survival and patency after AVF creation compared with control mice ( Figure IV in the online-only Data Supplement); however, AVF in Eph-B4 heterozygous mice develop thicker walls (day 21) compared with control mice. 28 Eph-B4 heterozygous mice treated with cavtratin showed reduced AVF wall thickness similar to control mice similarly treated (day 21; Figure 4K ), suggesting that stimulation of Cav-1 with cavtratin can rescue diminished Eph-B4 function, that is, Cav-1 is downstream of Eph-B4 ( Figure 4L ). In toto, these data suggest that Cav-1 signaling promotes AVF patency and may be a mechanism for Eph-B4-mediated AVF maturation.
Discussion
This study identifies Cav-1 as an essential regulator of flowmediated venous adaptation in mouse AVF model, suggesting that Cav-1 may be a potential pharmacological target for intervention to prevent failure of the venous conduits in patients with arterial occlusive disease or with ESRD. Using a mouse aortocaval fistula model, we show that stimulation of Cav-1 signaling with cavtratin suppressed AVF remodeling, resulting in improved AVF patency (Figure 4 ). In addition, we show that endothelial Cav-1 is a critical mediator of Eph-B4 function during AVF remodeling (Figure 3 ).
This report shows that Cav-1 regulates flow-mediated venous adaptation in the fistula environment, which is distinctly different than the arterial environment. 29 Understanding venous remodeling remains a significant clinical challenge because venous conduits that are used for hemodialysis access or vein grafts frequently fail because of insufficient venous remodeling. 10, 42, 43 Although some venous wall thickening and outward remodeling are consistent components of successful venous adaptation to the fistula and arterial environments, 6, 42 excessive remodeling may result in neointimal hyperplasia and clinical failure. Our data show that Cav-1 limits wall thickening and exuberant neointimal hyperplasia ( Figure 2C ) and that stimulation of Cav-1 signaling regulated AVF remodeling and reduced the risk of AVF failure (hazard ratio, 0.1; Figure 4F ), suggesting that Cav-1 may be another potential translational target.
Cav-1-the essential protein for the formation of plasmalemmal caveolae-plays a major role in mechanotransduction of dynamic shear stress changes in EC by interacting with several signaling protein families 18, 44 and has diverse functions, including regulation of inflammation, tumor progression, and atherosclerosis. 34, 45, 46 In the vascular system, Cav-1 inhibits arterial remodeling, 18 ,46 consistent with our data demonstrating an inhibitory function of Cav-1 during venous remodeling. Caveolae density in endothelial plasmalemma is increased in fistulae in vivo (Figure 1 ), consistent with previous in vitro studies showing that endothelial caveolae increase in response to shear stress. 47 However, the intracellular role of Cav-1 is separable from its role in caveolae biogenesis; caveolae formation and downstream signaling events occur through independent mechanisms. 48 Therefore, the direct implication of increased caveolae density in AVF or flow-mediated venous adaptation is currently unknown.
Cav-1 is predominantly expressed in adipocytes, vascular smooth muscle cells, ECs, and fibroblasts, with endothelial Cav-1 playing a central role in blood vessel, pulmonary, and cardiac functions. 32 In our AVF model, genetic global deletion of Cav-1 enhanced venous remodeling (Figure 2) , whereas reconstitution of Cav-1 specifically in the endothelium restored a similar remodeling pattern as seen in WT mice (Figure 3 ; Figure  II in the online-only Data Supplement); these data suggest an important role of endothelial Cav-1 in venous remodeling.
Cav-1 interacts with several RTK [20] [21] [22] [23] and G-proteincoupled receptors and regulates their signal-mediated vascular remodeling. 24, 25 For example, Cav-1 regulates AT1R (angiotensin II type I receptor) signal-mediated vascular remodeling in vascular smooth muscle cells and ECs. 24, 25 Cav-1 also regulates VEGFR-2 (vascular endothelial growth factor receptor-2) activity 49 ; the expression of VEGFR-2 is upregulated in the mouse AVF model. 28 Of translational interest, an RTK specifically associated with venous adaptation could be a target to improve AVF maturation; we focused on Eph-B4-an embryonic venous determinant active in adult endothelium-because we previously showed that Eph-B4 mediates vein graft adaptation and AVF maturation and that Cav-1 is a determinant of Eph-B4-mediated vein graft adaptation. Cav-1 appears to be a downstream effector of Eph-B4 function because Cav-1 is not critical for Eph-B4 tyrosine phosphorylation, but interactions with Cav-1 are critical aspects of Eph-B4 signaling and function. 27 In addition to these multiple pathways, Cav-1 mediation of venous remodeling may involve eNOS. eNOS is a resident protein of caveolae, and Cav-1 functions as a tonic inhibitor of eNOS-mediated signal transduction in vivo; 34, 40 Cav-1 KO mice show 5-fold increased systemic NO levels compared with WT littermates. 50 Our data that Cav-1 KO mice have increased eNOS phosphorylation (Figure 2 ) whereas stimulation of Cav-1 activity with cavtratin inhibits eNOS phosphorylation ( Figure 4 ) in AVF endothelium suggest that Cav-1 regulates AVF remodeling via eNOS and this is corroborated by the data showing reduced thickening with reduced eNOS activity ( Figure 2J and 2K ). As such, Cav-1 regulation of AVF remodeling is likely to involve eNOS as a mechanism; although cavtratin inhibits the functional activity of broad classes of proteins in vitro, cavtratin selectively targets eNOS and reduces its activity in ECs in vivo, 34 suggesting its potential for translational therapy.
Because veins ordinarily produce less NO compared with arteries, 51 the abnormal venous remodeling and increased eNOS phosphorylation in Cav-1 KO mice (Figure 2 ) suggests a potential mechanism for excessive neointimal hyperplasia that can lead to AVF failure. 50 Although NO is generally considered to play a protective role in the maintenance of vascular homeostasis, several studies that reported excessive NO as a contributor of vessel pathologies, 52 and our data may be consistent with this finding. Although short-term and occasional treatment with NO donors, such as those used to treat angina, is unlikely to cause vascular damage, our findings also indicate the need for caution in implementing long-term treatment with NO donors or with gene therapy-augmented NOS expression. 52 Augmentation of Cav-1 activity with cavtratin may provide a new therapeutic approach for regulation of NO production, perhaps mitigating the proinflammatory effects of excessive NO in EC 15, 34, 53 ; however, it is important to determine whether abnormal regulation of the NO pathway contributes to abnormal venous remodeling that is associated with AVF failure. Although NO is essential for venous remodeling, uncoupled eNOS generating superoxide anion and peroxynitrite may impair AVF function. 54 We have previously shown that nitrotyrosine-a surrogate marker for peroxynitrite-is elevated during AVF remodeling. 55 In summary, our data suggest that Cav-1 acts as an inhibitory regulator of flow-mediated venous adaptation; stimulation of Cav-1-specific signaling inhibited eNOS activity and improved AVF patency. Endothelial Cav-1 is also a critical regulator of Eph-B4-mediated AVF maturation, possibly reflecting the dual function of Cav-1 as a scaffold of the caveolar signaling platform, as well as a direct repressor of intracellular signaling events. Manipulation of an endothelial mechanosensor, such as Cav-1, may be a new strategy to improve AVF maturation and optimize fistula use for patients with ESRD.
